CYTOKINETICS INCORPOR

Cytokinetics to Announce Second Quarter Results on August 8, 2024

25 7 2024 15:00:00 提供 Nasdaq GlobeNewswire

Cytokinetics Announces Seven Upcoming Presentations at the European Society of Cardiology Congress 2024

16 7 2024 06:30:00 提供 Nasdaq GlobeNewswire

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

03 7 2024 15:00:00 提供 Nasdaq GlobeNewswire

Cytokinetics Announces Initiation of Phase 1 Study of Aficamten in Healthy Japanese Participants

17 6 2024 06:30:00 提供 Nasdaq GlobeNewswire

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

04 6 2024 15:00:00 提供 Nasdaq GlobeNewswire

Cytokinetics to Participate in June Investor Conferences

29 5 2024 15:00:00 提供 Nasdaq GlobeNewswire

Cytokinetics Announces Closing of Public Offering of Common Stock

28 5 2024 15:00:00 提供 Nasdaq GlobeNewswire

Cytokinetics Announces Pricing of Public Offering of Common Stock

22 5 2024 22:30:50 提供 Nasdaq GlobeNewswire

Cytokinetics Announces Proposed Public Offering of Common Stock

22 5 2024 15:02:00 提供 Nasdaq GlobeNewswire

Cytokinetics and Royalty Pharma Announce Expanded Strategic Funding Collaboration Totaling Up to $575 Million to Support Commercial Launch of Aficamten and to Advance R&D Pipeline

22 5 2024 15:00:00 提供 Nasdaq GlobeNewswire

Cytokinetics Hosts Muscle Biology-Focused Research Symposium: Contemporary Landscapes in Muscle Biology

17 5 2024 06:30:00 提供 Nasdaq GlobeNewswire

Cytokinetics Announces Five Presentations Related to Aficamten at the European Society of Cardiology Congress 2024

15 5 2024 06:30:00 提供 Nasdaq GlobeNewswire

Cytokinetics Announces Additional Results From SEQUOIA-HCM Presented in Late Breaking Clinical Trial Session at the European Society of Cardiology Heart Failure 2024 Congress

13 5 2024 08:33:00 提供 Nasdaq GlobeNewswire

Cytokinetics Announces Primary Results From SEQUOIA-HCM Presented in Late Breaking Clinical Trial Session at the European Society of Cardiology Heart Failure 2024 Congress and Published in the New England Journal of Medicine

13 5 2024 08:33:00 提供 Nasdaq GlobeNewswire

Cytokinetics Reports First Quarter 2024 Financial Results

08 5 2024 15:00:00 提供 Nasdaq GlobeNewswire

Cytokinetics Announces Topline Data From Phase 1 Clinical Study of CK-4021586

08 5 2024 06:30:00 提供 Nasdaq GlobeNewswire

Cytokinetics Announces Start of CEDAR-HCM, a Clinical Trial of Aficamten in a Pediatric Population With Symptomatic Obstructive Hypertrophic Cardiomyopathy

08 5 2024 06:30:00 提供 Nasdaq GlobeNewswire

Cytokinetics to Hold Annual Meeting of Stockholders

07 5 2024 15:00:00 提供 Nasdaq GlobeNewswire

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

02 5 2024 15:00:00 提供 Nasdaq GlobeNewswire

Cytokinetics to Host Investor Event and Conference Call to Discuss the Primary Results From SEQUOIA-HCM at the European Society of Cardiology Heart Failure 2024 Congress

29 4 2024 15:00:00 提供 Nasdaq GlobeNewswire